TABLE 1
FROM:
Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT
P Ljungman, D Engelhard, R de la Cámara, H Einsele, A Locasciulli, R Martino, P Ribaud, K Ward and C Cordonnier
BACK TO ARTICLETable 1. Evidence-based system used to determine strength of recommendations
| Strength of recommendations 1 | ||
| A | Strong evidence for efficacy and substantial clinical benefit | Strongly recommended |
| B | Strong or moderate evidence for efficacy, but only limited clinical benefit | Generally recommended |
| C | Insufficient evidence for efficacy; or efficacy does not outweigh possible adverse consequences (eg drug toxicity or interactions) or cost of chemoprophylaxis or alternative approaches | Optional |
| D | Moderate evidence against efficacy or adverse outcome | Generally not recommended |
| E | Strong evidence against efficacy or adverse outcome | Never recommended |
| Quality of evidence supporting recommendation | ||
| I | Evidence from at least one well-executed randomized trial | |
| II | Evidence from at least one well-designed clinical trial without randomization; cohort- or case-controlled analytic studies (preferably from more than one center; multiple time-series studies; or dramatic results from uncontrolled experiments | |
| III | Evidence from opinions of respected authorities based on clinical experience, descriptive studies, or reports from expert committees | |
Efficacy is defined as development of protective antibody response after vaccination.
